We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    COBRA REDUCE
Previous Study | Return to List | Next Study

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy (COBRA-REDUCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02594501
Recruitment Status : Unknown
Verified October 2020 by CeloNova BioSciences, Inc..
Recruitment status was:  Active, not recruiting
First Posted : November 3, 2015
Last Update Posted : October 26, 2020
Information provided by (Responsible Party):
CeloNova BioSciences, Inc.

Brief Summary:
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 3 or 6-month DAPT.

Condition or disease Intervention/treatment Phase
Angina, Stable Angina, Unstable Anticoagulants Device: COBRA PzF Device: Drug Eluting Stent Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 996 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Study Start Date : February 5, 2016
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : November 2021

Arm Intervention/treatment
Experimental: COBRA PzF
Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
Device: COBRA PzF
Active Comparator: Drug Eluting Stent
standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
Device: Drug Eluting Stent
Other Name: Xience/Promus, Resolute or Synergy

Primary Outcome Measures :
  1. BARC class >=2 bleeding after hospital discharge (or beyond 14 days, whichever is "later"). [ Time Frame: 6 months ]
  2. Composite of all cause death, myocardial infarction, definite and probable stent thrombosis or ischemic stroke [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Composite of all cause death, myocardial infarction, definite and probable stent thrombosis, ischemia-driven target lesion revascularization or ischemic stroke [ Time Frame: 12 months ]
  2. Composite of cardiac death and myocardial infarction [ Time Frame: 12 months ]
  3. Ischemia driven target lesion revascularization [ Time Frame: 12 months ]
  4. Definite and probable stent thrombosis [ Time Frame: 12 months ]
  5. Ischemic stroke [ Time Frame: 12 months ]
  6. BARC class 3-5 bleeding [ Time Frame: 6 months ]
  7. TIMI major bleeding; TIMI major and minor bleeding [ Time Frame: 6 months ]
  8. Acute Success Rates [ Time Frame: procedure ]
    Device success; Lesion success; Procedure success

  9. Health economic utility [ Time Frame: 12 months ]
    Total cardiovascular and bleeding related costs with cost effectiveness based on events avoided

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels).
  • Patient receiving or with an indication for new treatment with long-term oral anticoagulation with a coumadin derivatives or non-vitamin K oral anticoagulants.
  • Written, informed consent

Exclusion Criteria:

  • Cardiogenic shock
  • Target lesion located in left main trunk
  • Bifurcation interventions with a planned 2-stent strategy
  • Vessel size too small for implantation of a 2.5 mm stent by visual estimation
  • Patient requiring staging PCI procedure within 6 months after the index procedure
  • Patients requiring DAPT for more than 2 weeks after the index procedure
  • Contraindications or allergy to cobalt, chromium, platinum, polyzene-F, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months
  • Relevant hematologic deviations: platelet count <100x10^9 cells/L or >600x10^9 cells/L
  • Active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection
  • Malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance
  • Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding
  • Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives
  • Patient's inability to fully cooperate with the study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02594501

Show Show 48 study locations
Sponsors and Collaborators
CeloNova BioSciences, Inc.
Layout table for investigator information
Study Chair: Adnan Kastrati ISAResearch Center Deutsches Herzzentrum München
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: CeloNova BioSciences, Inc.
ClinicalTrials.gov Identifier: NCT02594501    
Other Study ID Numbers: COBRA 2015-01
First Posted: November 3, 2015    Key Record Dates
Last Update Posted: October 26, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Angina Pectoris
Angina, Unstable
Angina, Stable
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations